NCT01643226View on ClinicalTrials.gov

Safety and Efficacy Study of Corneal Collagen Cross-Linking in Eyes With Keratoconus

PHASE3CompletedINTERVENTIONAL
Enrollment

230

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

July 31, 2015

Study Completion Date

September 30, 2016

Conditions
Keratoconus
Interventions
DRUG

riboflavin solution

0.12% riboflavin ophthalmic solution

DRUG

placebo solution

0.0% riboflavin ophthalmic solution

DEVICE

KXL System

30 mW/cm2

Trial Locations (8)

10032

Columbia University Harkness Eye Institute, New York

15213

UPMC Eye Center, Pittsburgh

22102

See Clearly Vision, McLean

44195

Cleveland Clinic Cole Eye Institute, Cleveland

46260

Price Vision Group, Indianapolis

66211

Durrie Vision, Overland Park

92122

Gordon -Weiss Vision Institute, San Diego

07666

Cornea & Laser Eye Institute; Hersh Vision Group, Teaneck

Sponsors
All Listed Sponsors
lead

Glaukos Corporation

INDUSTRY

NCT01643226 - Safety and Efficacy Study of Corneal Collagen Cross-Linking in Eyes With Keratoconus | Biotech Hunter | Biotech Hunter